EE377 Cost-Effectiveness of Nirmatrelvir/Ritonavir in COVID-19 Patients at High-Risk for Progression in Spain
Abstract
Authors
C Peral JR Azanza JM Gonzalez del Castillo R Ferrando JM Molero Garcia A Soriano A Ariznavarreta Martin C Garí A De Lossada Juste V López Gómez